Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interferon chimeras
- Development stage
- Preclinical
- Lead developer
- Heligenics
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Recombinant human interferon chimeras is a pipeline program of 16 bi-functional chimeric proteins developed by Heligenics. These molecules are engineered using Heligenics' proprietary GigaAssay™ functional genomics platform, which enables high-throughput screening and optimization of biologic variants. The chimeras are designed to act as dual-receptor agonists targeting interferon receptors (such as Type I and Type II interferon receptors, or specific combinations of interferon-alpha, beta, and gamma pathways) to achieve enhanced immunomodulatory, antiproliferative, and antiviral activities. Heligenics is developing these candidates for the treatment of acute myeloid leukemia (AML), squamous cell carcinoma, polycythemia vera, and various viral infections.
- Other names
- bi-functional interferon chimerashybrid interferonsrecombinant human interferon chimera
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNGR1 (Interferon gamma receptor 1)IFNGR2 (Interferon gamma receptor 2)
Beyond the preview
Go deeper on recombinant human interferon chimeras.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interferon chimeras.